Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zynerba Pharmaceuticals, Inc.

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZYNE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.